$Vaccinex Inc.(VCNX)$  is my next choice to pop. I am very happy too see new treatment work, but most biotech companies fail . I invested in Humanigen, and now they are worth just over 1 million USD and almost bankrupt. I expect only one out of ten start up companies and biotech investments to give me a decent return.  The rest will flounder away or break even if I am lucky.  But it you find that one unicorn of an investment it can reward you very well.  So take your time and have a coffee before you decide to Invest your hard earned money. 

$Tempest Therapeutics Inc.(TPST)$ . Awesome research work hard. Beautiful 

$Tempest Therapeutics Inc.(TPST)$ More TPST type stocks to come will be good.. 

Hmm i dont know, but this post is a robbery, cheers

The market for weight loss drugs is big, but the changes for all of us are significant. ozempic and Ely Lilly's $Eli Lilly(LLY)$ future weight loss drugs will reduce the amount of calories we consume on average per day. The same drug will also eliminate many lifestyle diseases, and keep us all in the labor market for several extra years. These changes because of the drugs will have an impact - McDonalds falls in value, and we get more jobs filled, because of fewer sick people? (Just to mention a few examples) Which stocks are good to buy now, with these changes coming anytime soon? $Tempest Therapeutics Inc.(TPST)$

Oh man, this is some juicy stuff about the weight loss drug industry and how it's affecting the stock market. Walmart's big boss, John Furner, spilled the beans in an interview with Bloomberg, saying they've noticed a "slight change" in the eating habits of folks taking Ozempic and other weight loss drugs, compared to those who aren't popping these magic pills. It's like the impact of these pills is rippling through the business world!Now, these weight loss drugs, Ozempic, and Wegovy, they've been all the rage lately, and it's no surprise why. They work by making you feel less hungry – they mimic some fancy hormone that tells your brain, "Hey, you're full, stop stuffing your face!" UC Davis Health says it's all about that hormone game.And guess what? They're even making people less interes

The recent meteoric rise of Tempest Therapeutics Inc. has sent shockwaves through the investment landscape, reminiscent of previous market frenzies surrounding GameStop, AMC, and cryptocurrency. While the surge in stock value was triggered by promising study results for its cancer treatment TPST-1120, it’s essential to approach such hype stocks with caution, considering the underlying investing fundamentals and the potential risks associated with volatile market surges. $Tempest Therapeutics Inc.(TPST)$  1. Tempest Therapeutics’ Spectacular Surge: The Study Results and Stockholder Rights Plan • Shares of Tempest Therapeutics skyrocketed by an unprecedented 4,000% following the announcement of positive study results for its investigational ca

$Tempest Therapeutics Inc.(TPST)$   The world of investing is often a thrilling rollercoaster ride, with stocks surging and plummeting at a moment's notice. One such recent surge that has caught my attention is Tempest, a company in the biotech sector. The question on many minds is whether to trade this meme biotech stock and whether their treatment could potentially revolutionize liver cancer care. First, let's address the surge of Tempest. I can't help but be intrigued by the rapid rise of this biotech stock. Meme stocks tend to garner attention due to their sudden price fluctuations driven by social media hype and investor sentiment. However, it's crucial to approach them with caution, considering their inherent volatility. While the surge

$Tempest Therapeutics Inc.(TPST)$ Then what's going on🫠

Founded in 2011, California-based $Tempest Therapeutics Inc.(TPST)$ deals primarily in developing treatments for cancer patients.The cancer therapies company surged 4000% during the trading hours after it reported positive results for its TPST-1120 drug candidate in clinical study. HCC (Hepatocellular Carcinoma) is an aggressive cancer, with over 900,000 people diagnosed worldwide every year. Furthermore, it is projected to become the third leading cause of cancer-related deaths by 2030.Clinical trial shows significant progress of its drug in treating liver cancerTempest conducted the study that sent TPST stock up in conjunction with Swiss healthcare company $Roche Holding Ltd(RHHBY)